	US 12,220,393 B2
	Compositions and methods for the treatment of zika viral diseases
Albert Crum, Rhinebeck, NY (US); and Julia Hilliard, Atlanta, GA (US)
Assigned to ProImmune Company LLC, Rhinebeck, NY (US); and Georgia State University Research Foundation, Atlanta, GA (US)
Appl. No. 16/610,488
Filed by The ProImmune Company LLC, Rhinebeck, NY (US); and Georgia State University Research Foundation, Atlanta, GA (US)
PCT Filed May 1, 2018, PCT No. PCT/US2018/030500 § 371(c)(1), (2) Date Nov. 1, 2019, PCT Pub. No. WO2018/204394, PCT Pub. Date Aug. 11, 2018.
Claims priority of provisional application 62/500,430, filed on May 2, 2017.
Prior Publication US 2020/0155492 A1, May 21, 2020
Int. Cl. A61K 31/198 (2006.01); A61K 33/04 (2006.01); A61P 31/14 (2006.01); B82Y 5/00 (2011.01)

CPC A61K 31/198 (2013.01) [A61K 33/04 (2013.01); A61P 31/14 (2018.01); B82Y 5/00 (2013.01)]

20 Claims

1. A method for treating Zika viral disease in a subject infected with Zika virus, comprising: administering to the subject, an effective amount of a composition comprising: glycine, L-cystine, a glutamate source selected from the group consisting of glutamine and glutamic acid, and a selenium source.